.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Federal Trade Commission
Colorcon
McKinsey
McKesson
Julphar
Baxter
Novartis
Daiichi Sankyo

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,384,020

« Back to Dashboard

Which drugs does patent 6,384,020 protect, and when does it expire?


Patent 6,384,020 protects ADDERALL 10, ADDERALL 12.5, ADDERALL 15, ADDERALL 20, ADDERALL 30, ADDERALL 5, and ADDERALL 7.5, and is included in one NDA. There has been one Paragraph IV challenge on Adderall 30.

Protection for ADDERALL 10 has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has six patent family members in six countries.

Summary for Patent: 6,384,020

Title: Rapid immediate release oral dosage form
Abstract:A pharmaceutical composition comprising lactitol and one or more amphetamine salts in a rapid release formulation.
Inventor(s): Flanner; Henry H. (Montgomery Village, MD), Chang; Rong-Kun (Rockville, MD), Pinkett; Jill E. (Baltimore, MD), Wassink; Sandra E. (Frederick, MD), White; Lisa R. (Damascus, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:09/611,098
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Teva WomensADDERALL 10amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-007Feb 13, 1996DISCNYesNo► Subscribe► Subscribe► SubscribeY
Teva WomensADDERALL 12.5amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-012Aug 31, 2000DISCNYesNo► Subscribe► Subscribe► SubscribeY
Teva WomensADDERALL 15amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-013Aug 31, 2000DISCNYesNo► Subscribe► Subscribe► SubscribeY
Teva WomensADDERALL 20amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-008Feb 13, 1996DISCNYesNo► Subscribe► Subscribe► SubscribeY
Teva WomensADDERALL 30amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-010May 12, 1997DISCNYesNo► Subscribe► Subscribe► SubscribeY
Teva WomensADDERALL 5amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-009May 12, 1997DISCNYesNo► Subscribe► Subscribe► SubscribeY
Teva WomensADDERALL 7.5amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL011522-011Aug 31, 2000DISCNYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,384,020

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia6089200► Subscribe
Canada2378336► Subscribe
European Patent Office1202739► Subscribe
Japan2003504406► Subscribe
MexicoPA02000290► Subscribe
World Intellectual Property Organization (WIPO)0105407► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Accenture
US Department of Justice
Johnson and Johnson
Federal Trade Commission
McKesson
AstraZeneca
McKinsey
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot